SCYNEXIS, Inc. reported its financial results for the second quarter of 2025, revealing a license agreement revenue of $1.4 million, a significant increase from $736,000 in the same period last year. For the first half of 2025, total revenue was $1.6 million, down from $2.1 million in the first half of 2024. The company recorded a net loss of $6.9 million for the quarter, a 52% improvement compared to a net loss of $14.5 million in the prior year. The loss per share for the second quarter was $0.14, compared to $0.30 in the same quarter of 2024.
Operating expenses for the second quarter totaled $10.9 million, up from $10.0 million in the same period last year. Research and development expenses increased to $7.1 million from $6.8 million, driven by higher costs in chemistry, manufacturing, and controls, as well as preclinical expenses. Selling, general, and administrative expenses also rose to $3.8 million, reflecting a 20% increase from $3.2 million in the previous year. The company’s total operating expenses for the first half of 2025 were $19.8 million, a decrease from $20.9 million in the first half of 2024.
In terms of strategic developments, SCYNEXIS is focused on advancing its proprietary antifungal platform, particularly the drug ibrexafungerp, which has been licensed to GlaxoSmithKline (GSK). The company is currently conducting the Phase 3 MARIO study for ibrexafungerp, which was temporarily placed on clinical hold due to manufacturing concerns but has since resumed. In May 2025, SCYNEXIS billed GSK a $10 million milestone related to the study's continuation. However, a dispute has arisen regarding GSK's intention to terminate the study, which SCYNEXIS contests.
As of June 30, 2025, SCYNEXIS reported total assets of $60.7 million, a decrease from $90.6 million at the end of 2024. The company’s cash and cash equivalents stood at $11.0 million, down from $16.1 million at the end of the previous year. The accumulated deficit increased to $388.8 million. The company has indicated that its current capital resources are sufficient to fund operations for at least the next 12 months, although it may need to raise additional capital through equity offerings or other financing methods to support ongoing research and development activities.
Looking ahead, SCYNEXIS remains committed to developing innovative antifungal solutions to address the rising threat of drug-resistant infections. The company is also navigating challenges related to its licensing agreements and ongoing clinical trials, which could impact its financial outlook. The company has until December 17, 2025, to regain compliance with Nasdaq's minimum bid price requirement, following a notification received in June 2025 regarding its stock price falling below the $1.00 threshold.
About SCYNEXIS INC
Scynexis, Inc. develops innovative antifungal medicines, focusing on a proprietary platform of triterpenoid agents called fungerps. Its lead product, ibrexafungerp, is approved for vulvovaginal candidiasis and under development for systemic fungal infections. The company collaborates globally, leveraging licensing agreements and clinical trials to address resistant fungal pathogens, with a competitive edge in oral, broad-spectrum, fungicidal antifungals targeting unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.